SCHEMBL3050459

SCHEMBL3050459

O=S(=O)(Cc1ccccc1)c1ccc(S(=O)(=O)Nc2nccs2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN3A Q9NY46 6/20 0.65
PKM P14618 4/20 0.63
LMNA P02545 3/20 0.62
ALDH1A1 P00352 3/20 0.62
SMN1; SMN2 Q16637 2/20 0.62
KDM4E B2RXH2 1/20 0.62
CYP2C9 P11712 1/20 0.62
EDNRA P25101 1/20 0.62
SLC6A4 P31645 1/20 0.62
ADRA1A P35348 1/20 0.62
PRMT6 Q96LA8 1/20 0.62
TDP1 Q9NUW8 1/20 0.62
SCN1A P35498 2/20 0.59
SCN5A Q14524 2/20 0.59
SCN8A Q9UQD0 2/20 0.59
SCN1B Q07699 1/20 0.59
MEN1 O00255 1/20 0.57
KMT2A Q03164 1/20 0.57
CYP1A2 P05177 1/20 0.56
ATM Q13315 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3061126 0.88 SCN3A (0.73) SCN3APKMLMNAALDH1A1SMN1; SMN2
SCHEMBL3056051 0.87 SCN3A (0.65) SCN3APKMLMNAALDH1A1SMN1; SMN2
SCHEMBL326633 0.85 ALDH1A1 (0.71) SCN3APKMLMNAALDH1A1SMN1; SMN2
Hydrochloric Acid SCHEMBL27575105 0.84 ALDH1A1 (0.69) SCN3APKMLMNAALDH1A1SMN1; SMN2
SCHEMBL3058171 0.84 SCN3A (0.64) SCN3APKMLMNAALDH1A1SMN1; SMN2
SCHEMBL3065005 0.84 SCN3A (0.81) SCN3APKMLMNAALDH1A1SMN1; SMN2
SCHEMBL16646055 0.83 SCN3A (0.68) SCN3APKMLMNAALDH1A1SMN1; SMN2
SCHEMBL3070565 0.83 ALDH1A1 (0.68) SCN3APKMLMNAALDH1A1SMN1; SMN2
SCHEMBL15116269 0.79 SCN3A (1.00) SCN3APKMLMNAALDH1A1SMN1; SMN2
SCHEMBL3161304 0.79 SCN3A (1.00) SCN3APKMALDH1A1KDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140357685-A1 Sodium Channel Inhibitors ICAGEN INC (US) 2014-12-04 US disclosed
US-8853250-B2 Sodium channel inhibitors ICAGEN, INC. (US) 2014-10-07 US disclosed
EP-2175728-B1 SODIUM CHANNEL INHIBITORS ICAGEN INC (US) 2014-09-10 EP disclosed
US-20100267782-A1 SODIUM CHANNEL INHIBITORS ICAGEN, INC (US) 2010-10-21 US disclosed
EP-2175728-A1 SODIUM CHANNEL INHIBITORS Icagen, Inc. (US) 2010-04-21 EP disclosed
WO-2009012241-A1 SODIUM CHANNEL INHIBITORS ICAGEN, INC. (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140357685-A1 Sodium Channel Inhibitors TRPV1, SCN1A, SCN2A SCN3A 8/4885PKM 2661/4885LMNA 3041/4885
US-20100267782-A1 SODIUM CHANNEL INHIBITORS TRPV1, SCN1A, SCN2A SCN3A 8/4885PKM 2661/4885LMNA 3041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.